# Obrixtamig

Source: https://onco.cc/drugs/obrixtamig/  
OnCo record `obrixtamig` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Obrixtamig is an antibody with two arms: one grabs DLL3, a protein on the surface of most neuroendocrine carcinomas, and the other grabs a T cell, pulling the killer cell onto the cancer. It is in a phase 3 trial for neuroendocrine carcinomas outside the lung.

## Summary

Obrixtamig (BI 764532) is Boehringer Ingelheim's DLL3-directed T-cell engager, a class established by tarlatamab in small-cell lung cancer. DLL3 is expressed on the surface of most small-cell lung cancers and extrapulmonary neuroendocrine carcinomas but almost no normal adult tissue. It is given intravenously with step-up dosing to limit cytokine release syndrome.

The phase 2 DAREON-5 trial reported responses in DLL3-positive small-cell lung cancer and extrapulmonary neuroendocrine carcinoma, and the phase 3 DAREON-NEC-1 trial is testing obrixtamig with carboplatin and etoposide first line in DLL3-positive extrapulmonary neuroendocrine carcinoma, the first phase 3 dedicated to that disease. The extrapulmonary neuroendocrine carcinoma page names it with peluntamig and ZG006 among the DLL3 engagers in trials.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-17
- Also known as: BI 764532; BI-764532
- Tags: subtype-drugs-wave
- Code: BI 764532
- Modality: DLL3 x CD3 bispecific T-cell engager
- Mechanism: One arm binds delta-like ligand 3 on neuroendocrine carcinoma cells and the other binds CD3 on T cells, forcing an immune synapse that makes the T cell kill the tumour cell.

## Connected records

- drugs: [Peluntamig](https://onco.cc/drugs/peluntamig/), [Tarlatamab](https://onco.cc/drugs/tarlatamab/), [ZG006](https://onco.cc/drugs/zg006/)
- cancers: [Extrapulmonary neuroendocrine carcinoma](https://onco.cc/cancers/extrapulmonary-nec/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD3](https://onco.cc/targets/cd3/), [DLL3](https://onco.cc/targets/dll3/)
- companies: [Boehringer Ingelheim](https://onco.cc/companies/boehringer-ingelheim/)

---
JSON: https://onco.cc/api/v1/entities/obrixtamig.json